Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PAL Adjuvant (FB-631) with Seasonal Influenza Vaccine in Healthy Adults
NCT02188810Phase 1Unknown
- Sponsor
- Folia Biotech Inc.
- Start
- Apr 2014
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of bexmarilimab in influenza (6 arms), sponsored by Folia Biotech Inc. Primary endpoint: Safety at 3 years. Status: unknown.
02
Drugs
bexmarilimab
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02188810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02188810.